Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00306111
Status:
COMPLETED
Last Update Posted:
2014-05-29
First Post:
2006-03-20
Brief Title:
Pegfilgrastim vs Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Pegfilgrastim Versus Filgrastim - Intraindividual Comparison of Quantity and Quality of Mobilized Peripheral Blood Stem Cells in Patients With Non Hodgkin-lymphoma
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the ability of pegfilgrastim vs filgrastim to mobilize peripheral blood stem cells in patients with Non Hodgkin-lymphoma in an intraindividual study
Detailed Description:
Patients with Non Hodgkin-lymphoma undergoing stem cell mobilization for planned high-dose therapy will be treated with two cycles of chemotherapy etoposide ifosfamide cisplatin epirubicin either followed by daily administration of filgrastim first cycle or pegfilgrastim once after the second cycle The number of circulating cluster of differentiation 34 cells colony-forming units and primitive progenitors will be analyzed at corresponding time points Peripheral blood stem cells will be collected after the second cycle of chemotherapy by leukapheresis After the second cycle high-dose therapy with peripheral blood stem cell support will be administered the protocol will be chosen according to the diagnosis including total body irradiation-containing regimens
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None